New CAR-T therapy targets tough lymphoma in early trial
NCT ID NCT07053670
First seen Nov 17, 2025 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This early-phase study tests a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. The main goals are to check safety and find the right dose, while also looking at how well it shrinks tumors. Participants will be followed for up to 15 years to monitor long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhang, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT1190B CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could provide a new treatment option for patients with hard-to-treat B-cell lymphoma that has returned or not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 27 participants, so results are preliminary. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.